MedTrace Logo

Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation

NCT02083809 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2020-11-27

Study results available
· View outcomes & findings →

Summary

Currently, there is very little research to identify ways to decrease blood loss during D\&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D\&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.

Conditions

  • Abortion
  • Dilation and Evacuation
  • Hemorrhage
  • Blood Loss

Interventions

DRUG

intravenous oxytocin

30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)

DRUG

Intravenous Fluids and Electrolytes

500 ml of inert IV fluid

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083809 on ClinicalTrials.gov